288 related articles for article (PubMed ID: 37068524)
1. Overview of the therapeutic strategies for ER positive breast cancer.
Blakely B; Shin S; Jin K
Biochem Pharmacol; 2023 Jun; 212():115552. PubMed ID: 37068524
[TBL] [Abstract][Full Text] [Related]
2. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
3. Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital.
Bardia A; Iafrate JA; Sundaresan T; Younger J; Nardi V
Oncologist; 2016 Sep; 21(9):1035-40. PubMed ID: 27551012
[TBL] [Abstract][Full Text] [Related]
4. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
5. Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer.
Patel JM; Jeselsohn RM
Adv Exp Med Biol; 2022; 1390():171-194. PubMed ID: 36107319
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
7. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.
Hartmaier RJ; Trabucco SE; Priedigkeit N; Chung JH; Parachoniak CA; Vanden Borre P; Morley S; Rosenzweig M; Gay LM; Goldberg ME; Suh J; Ali SM; Ross J; Leyland-Jones B; Young B; Williams C; Park B; Tsai M; Haley B; Peguero J; Callahan RD; Sachelarie I; Cho J; Atkinson JM; Bahreini A; Nagle AM; Puhalla SL; Watters RJ; Erdogan-Yildirim Z; Cao L; Oesterreich S; Mathew A; Lucas PC; Davidson NE; Brufsky AM; Frampton GM; Stephens PJ; Chmielecki J; Lee AV
Ann Oncol; 2018 Apr; 29(4):872-880. PubMed ID: 29360925
[TBL] [Abstract][Full Text] [Related]
8. Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer.
Xia S; Lin Q
Technol Cancer Res Treat; 2022; 21():15330338221090351. PubMed ID: 35450488
[TBL] [Abstract][Full Text] [Related]
9. An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer.
Scherer SD; Riggio AI; Haroun F; DeRose YS; Ekiz HA; Fujita M; Toner J; Zhao L; Li Z; Oesterreich S; Samatar AA; Welm AL
Breast Cancer Res; 2021 Oct; 23(1):100. PubMed ID: 34717714
[TBL] [Abstract][Full Text] [Related]
10. ESR1 mutations in breast cancer.
Dustin D; Gu G; Fuqua SAW
Cancer; 2019 Nov; 125(21):3714-3728. PubMed ID: 31318440
[TBL] [Abstract][Full Text] [Related]
11. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.
Jeselsohn R; Buchwalter G; De Angelis C; Brown M; Schiff R
Nat Rev Clin Oncol; 2015 Oct; 12(10):573-83. PubMed ID: 26122181
[TBL] [Abstract][Full Text] [Related]
12. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
13. ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.
Herzog SK; Fuqua SAW
Br J Cancer; 2022 Feb; 126(2):174-186. PubMed ID: 34621045
[TBL] [Abstract][Full Text] [Related]
14. The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
Grinshpun A; Sandusky ZM; Jeselsohn R
Hematol Oncol Clin North Am; 2023 Feb; 37(1):169-181. PubMed ID: 36435608
[TBL] [Abstract][Full Text] [Related]
15. Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
Robinson DR; Wu YM; Vats P; Su F; Lonigro RJ; Cao X; Kalyana-Sundaram S; Wang R; Ning Y; Hodges L; Gursky A; Siddiqui J; Tomlins SA; Roychowdhury S; Pienta KJ; Kim SY; Roberts JS; Rae JM; Van Poznak CH; Hayes DF; Chugh R; Kunju LP; Talpaz M; Schott AF; Chinnaiyan AM
Nat Genet; 2013 Dec; 45(12):1446-51. PubMed ID: 24185510
[TBL] [Abstract][Full Text] [Related]
16. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing.
Ross DS; Zehir A; Brogi E; Konno F; Krystel-Whittemore M; Edelweiss M; Berger MF; Toy W; Chandarlapaty S; Razavi P; Baselga J; Wen HY
Mod Pathol; 2019 Jan; 32(1):81-87. PubMed ID: 30158597
[TBL] [Abstract][Full Text] [Related]
18. Preexisting Somatic Mutations of Estrogen Receptor Alpha (
Dahlgren M; George AM; Brueffer C; Gladchuk S; Chen Y; Vallon-Christersson J; Hegardt C; Häkkinen J; Rydén L; Malmberg M; Larsson C; Gruvberger-Saal SK; Ehinger A; Loman N; Borg Å; Saal LH
JNCI Cancer Spectr; 2021 Apr; 5(2):. PubMed ID: 33937624
[TBL] [Abstract][Full Text] [Related]
19. ESR1 activating mutations: From structure to clinical application.
Grinshpun A; Chen V; Sandusky ZM; Fanning SW; Jeselsohn R
Biochim Biophys Acta Rev Cancer; 2023 Jan; 1878(1):188830. PubMed ID: 36336145
[TBL] [Abstract][Full Text] [Related]
20. Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial.
Paoletti C; Schiavon G; Dolce EM; Darga EP; Carr TH; Geradts J; Hoch M; Klinowska T; Lindemann J; Marshall G; Morgan S; Patel P; Rowlands V; Sathiyayogan N; Aung K; Hamilton E; Patel M; Armstrong A; Jhaveri K; Im SA; Iqbal N; Butt F; Dive C; Harrington EA; Barrett JC; Baird R; Hayes DF
Clin Cancer Res; 2018 Dec; 24(23):5860-5872. PubMed ID: 30082476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]